STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more
The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews
STAT+: As China’s drug industry races ahead, its GLP-1 race is accelerating too
To understand what China’s fast-developing drug industry might mean for global pharmaceutical companies, look no further than the market for GLP-1 drugs.
Bariatric surgery programs face upheaval amid growing GLP-1 use for weight loss
At Roxborough Memorial Hospital in Philadelphia, surgeon Piotr Krecioch has his hands full launching a program offering surgical interventions to treat obesity. One in three Philadelphians are living with obesity, putting them at higher risk of chronic conditions like diabetes and heart disease, but these days fewer are seeking the bariatric surgical procedures long considered a leading medical treatment for the condition.
Despite Side Effects, People Continue Taking Ozempic for Weight Loss
People who lose weight with GLP-1 drugs are likely to continue using the medication despite the side effects. Image Credit: geckophotos/Getty Images
A recent study found that many people using GLP-1 drugs for weight loss choose to continue the medication despite unpleasant side effects.
The researchers found that in addition to weight loss, perceived reductions in appetite and cravings were the strongest predictors of satisfaction and intention to continue treatment with Ozempic.
Will Ozempic-style patches help you lose weight? Two experts explain
Could a simple patch, inspired by the weight-loss drug Ozempic, really help you shed excess kilos without the pain and effort of an injection?
Obesity rates are rising, despite GLP-1s. What does it mean?
By 2030, nearly half of all American adults will have obesity, according to research published in the New England Journal of Medicine. In every single state, researchers expect at least 35% of adults to have a body mass index of 30 or higher, the threshold that defines obesity. That prediction may come as a shock, as weight loss medications like Wegovy and Zepbound become more popular and more affordable.
Combining GLP-1 drugs with hormones may lower uterine cancer risk
Adding GLP-1 medications like Ozempic to progestin therapy could cut the risk of developing endometrial cancer. A retrospective study published in the journal JAMA Network Open found that women using this combination had a much lower risk of developing the disease than those on progestins alone.
Lilly appeals retatrutide classification ruling in case that could impact compounders
Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it.
On Thursday, Lilly filed a notice …
FDA Leader Accused of Sexual Harassment; RFK Jr.’s Toilet Comment; GLP-1s and Scurvy
(MedPage Today) — Note that some links may require registration or subscription.
FDA vaccine chief Vinay Prasad, MD, MPH, who made the controversial decision to refuse to review Moderna’s mRNA flu vaccine, has been accused of sexual harassment…
Lilly Prepares $1B+ Orforglipron Stock Ahead of Approval as Novo Brings Wegovy Pill Overseas
Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping up manufacturing investments for the weight-loss pill.